United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlaxoSmithKline

Halozyme Therapeutics

GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme Therapeutics Inc (NASDAQ: HALO) to gain access to Halozyme's Enhanze drug delivery technology for use against four HIV targets. ViiV Healthcare will pay $40 million upfront and up to $175 million in milestones, as well as mid-single-digit royalties on future sales.

GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal

LONDON & SAN DIEGO--(BUSINESS WIRE)--ViiV HC and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to develop ultra-long-acting HIV medicines

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV

LONDON and SAN DIEGO, June 22, 2021 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclusive access to Halozyme's ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV.  Under the terms of the agreement, ViiV Healthcare will make an upfront payment of $40 million to Halozyme for the exclusive license to four HIV small and large molecule targets and is obligated to make potential future payments of up to $175 million in development and commercial milestones per target, subject to achievement of specified development and commercial milestones, including certain specified sales milestones.

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

BioNTech SE

The Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine has received provisional approval for use in the age group 12 to 15 from New Zealand's medical regulator, Stuff reported Monday (local time). What Happened: The vaccine already stands approved for those 16 years and older in the country.

Pfizer COVID-19 Vaccine Approved For 12-15 Age Group In New Zealand

Efficacy against variants is showing the drug is the gold standard in preventing COVID.

Pfizer's COVID Vaccine Is Even More Amazing Than You Think

Moderna

The news continued to be good for mRNA vaccines.

What to Make of the CDC's Latest Efficacy Data on Pfizer's and Moderna's COVID Vaccines

Eli Lilly

We think that Pfizer currently is a better pick compared to Eli Lilly & Company. PFE stock trades at about 5x trailing revenues, compared to around 8x for LLY.

Is Pfizer Stock A Better Bet Compared To Eli Lilly?

A second study this week has demonstrated a new Covid-19 treatment that can reduce deaths in patients suffering from the most severe symptoms of the virus. Pfizer Inc (NYSE:PFE) said almost 40% fewer patients (18%) treated with Xeljanz, an oral rheumatoid arthritis drug, died in the study compared with those given a placebo (29%).

Pfizer treatment cuts severe Covid-19 deaths by 40% in trial

Pfizer Inc (NYSE: PFE) said that its oral rheumatoid arthritis drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study's primary goal. Results of the study, which tested the drug in 289 hospitalized adult patients with respiratory illness due to the infection, were published in the New England Journal of Medicine.

Pfizer's Xeljanz Cuts Incidence Of Death, Respiratory Failure In COVID-19 Patients, Brazilian Study Shows

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein today announced that the New England Journal of Medicine has published positive findings from the STOP-COVID study (NCT04469114) evaluating the efficacy and safety of oral Janus kinase (JAK) inhibitor tofacitinib in 289 hospitalized adult patients with COVID-19 pneumonia who were not on ventilation. The trial was a research collaboration between Pfizer and

Data Published in New England Journal of Medicine Shows Pfizer's Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

By the end of 2022, there should be enough Covid vaccine doses for most world leaders to successfully inoculate their populations, Pfizer's Albert Bourla said.

Pfizer CEO sees a return to 'normal' globally by the end of 2022

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, July 28, 2021. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2021 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Info

Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts

The big drugmaker's bottom line won't be helped, but millions of people across the world will.

Why Pfizer's About to Sell 500 Million COVID Vaccine Doses Without Making a Dime

Coca-Cola

Kroger

SpartanNash

Vanguard High Dividend Yield ETF

Verizon

The journey to financial freedom does not take breaks and one must continue to persevere through uncertainty, put cash to work and push that forward dividend income forward. I invested quite a bit into a Vanguard Exchange Traded Fund (ETF). This has helped me amass an investment with Vanguard of over $30,000 since last year.

Dividend Stock Purchase: Lanny's May 2021 Summary

While most agree booster shots are likely to be needed, scientists don't have many answers on when this might be.

When Will You Need A Covid Booster Shot? Pfizer Monitors Breakthrough Infections As Experts Say More Data Is Needed

How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?

Novavax

It was "better late than never" for Novavax, Inc. (NASDAQ: NVAX), as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus. Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) and Moderna, Inc. (NASDAQ: MRNA), both of which have authorized vaccines in the market.

Novavax Vs. Pfizer Vs.

There's a pretty good case to be made that it is.

Is Pfizer Stock Undervalued?

Hasbro

PepsiCo

You don't have to settle for tiny yields today.

4 High-Yield Dividend Stocks to Watch

The CDC reports cases of myocarditis and pericarditis following inoculation with mRNA vaccines of Moderna (MRNA) and Pfizer (PFE). The authority schedules meeting next week to investigate these reports.

COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart

Johnson & Johnson

Teens represent the next big group needing vaccination.

Which Company Will Dominate the Teen Vaccination Market This Fall?

Pfizer Can Now Vaccinate Teens. Will This Boost Orders?

Albert Bourla stressed that Pfizer's jab has so far proven effective against existing variants.

Pfizer CEO Says New Shot Could Be Made Within 100 Days To Tackle Variants If Needed

The stock price of Pfizer Inc. (NYSE: PFE) increased by over 2% during intraday trading. This is why it happened.

PFE Stock Price: Over 2% Increase Explanation

Apple

Costamare

Freeport-McMoRan

McDonald's

Walmart

Here are seven value stocks from fundamentally strong companies that look good for upside and provide investors with dividend income. The post Anti-Meme Stocks: 7 Value Stock Picks for Common Sense Investors appeared first on InvestorPlace.

News for Pfizer Stock (PFE)